Our model
The journey from target identification to developing a new drug treatment can be long and challenging. At Axxam, we work closely with our clients’ scientists to form a unified team, sharing our extensive expertise in assay development, hit identification, and hit-to-lead activities with the goal of overcoming the challenges together through trusted collaboration.
DiscoveryMAXX - start right, progress faster
Axxam offers the possibility to run discovery programs from target assessment all the way to compounds with a profile suitable for the in vivo proof-of-concept in relevant animal models. The DiscoveryMAXX package is a comprehensive program that seamlessly continues from assay development through high-throughput screening (HTS) and hit qualification to hit-to-lead optimization. Hit compounds can be optimized towards an agreed target product profile by combining expert medicinal chemistry with our in vitro biology and pharmacology platforms, as well as other required capabilities in-sourced from trusted partners, for individual project needs, such as in vivo DMPK. Depending on the target of interest and available data on either target or ligand structure(s), the process will also be supported by computational chemistry.
DiscoveryMAXX provides clients with the opportunity to have a single partner driving and coordinating their discovery project from target selection to the generation of a small molecule lead candidate for in vivo testing. Thus DiscoveryMAXX completes our ambition to translate innovative biology into quality chemistry.
Our partners
To enhance our service offering, we collaborate with trusted partners, covering numerous steps required to advance hit identification projects initiated at Axxam through the drug discovery and part of the development process.
By establishing a consortium of centers of excellence with specialized drug discovery platforms, we provide best-in-class, fully integrated drug discovery services that can seamlessly integrate with clients’ preferred providers.
